These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34702245)

  • 21. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
    Theilade S; Lyngbaek S; Hansen TW; Eugen-Olsen J; Fenger M; Rossing P; Jeppesen JL
    J Intern Med; 2015 Mar; 277(3):362-371. PubMed ID: 24830873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
    Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
    Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum levels of soluble urokinase plasminogen activator receptor as a new inflammatory marker in adolescent obesity.
    Can U; Buyukinan M; Yerlikaya FH
    Indian J Med Res; 2017 Mar; 145(3):327-333. PubMed ID: 28749394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status.
    Heraclides A; Jensen TM; Rasmussen SS; Eugen-Olsen J; Haugaard SB; Borch-Johnsen K; Sandbæk A; Lauritzen T; Witte DR
    Diabetologia; 2013 Jul; 56(7):1542-6. PubMed ID: 23613086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study.
    Rasmussen LJ; Ladelund S; Haupt TH; Ellekilde G; Poulsen JH; Iversen K; Eugen-Olsen J; Andersen O
    Emerg Med J; 2016 Nov; 33(11):769-775. PubMed ID: 27590986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Activation Mediates the Association of Advanced Hepatic Fibrosis With Adverse Outcomes in Patients With Coronary Artery Disease.
    Jain V; Mehta A; Lee TB; Liu C; Chew NWS; Ko YA; Gold ME; Gold DA; Vatsa N; Desai SR; Kim JH; Rahbar A; Haroun Y; Ejaz K; Hayek SS; Siddiqui MS; Salloum FN; Sperling LS; Sanyal AJ; Quyyumi AA
    J Am Heart Assoc; 2023 Dec; 12(24):e031230. PubMed ID: 38063161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of soluble urokinase plasminogen activator receptor (suPAR) as an inflammatory biomarker in obese children.
    Kosecik M; Dervisoglu P; Koroglu M; Isguven P; Elmas B; Demiray T; Altindis M
    Int J Cardiol; 2017 Feb; 228():158-161. PubMed ID: 27865178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations between plasma inflammatory markers and psychotic disorder, depressive disorder and generalised anxiety disorder in early adulthood: A nested case-control study.
    Mongan D; Raj Susai S; Föcking M; Byrne JF; Zammit S; Cannon M; Cotter DR
    Brain Behav Immun; 2023 Jul; 111():90-100. PubMed ID: 37004760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between levels of plasma-soluble urokinase plasminogen activator receptor (suPAR) and presence of migraine attack and aura.
    Yılmaz N; Yılmaz M; Sirin B; Yılmaztekin S; Kutlu G
    J Recept Signal Transduct Res; 2017 Oct; 37(5):447-452. PubMed ID: 28553881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis.
    Toldi G; Szalay B; Bekő G; Kovács L; Vásárhelyi B; Balog A
    Joint Bone Spine; 2013 Jan; 80(1):96-8. PubMed ID: 22999906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome.
    Raggam RB; Wagner J; Prüller F; Grisold A; Leitner E; Zollner-Schwetz I; Valentin T; Krause R; Hoenigl M
    J Intern Med; 2014 Dec; 276(6):651-8. PubMed ID: 24645798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children.
    Weidemann DK; Abraham AG; Roem JL; Furth SL; Warady BA
    Am J Kidney Dis; 2020 Aug; 76(2):194-202. PubMed ID: 31987488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
    Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
    Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease.
    Fagerberg B; Borné Y; Barregard L; Sallsten G; Forsgard N; Hedblad B; Persson M; Engström G
    Environ Res; 2017 Jan; 152():185-191. PubMed ID: 27792942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Could soluble urokinase plasminogen receptor (suPAR) be used as a diagnostic biomarker for ventilator-associated pneumonia?
    Sunnetcioglu A; Sunnetcioglu M; Adıyaman F; Binici I; Soyoral L
    Clin Respir J; 2017 Nov; 11(6):925-930. PubMed ID: 26683264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum Levels of Soluble Urokinase Plasminogen Activator Receptor in Infants with Late-onset Sepsis.
    Okulu E; Arsan S; Akin IM; Ates C; Alan S; Kilic A; Atasay B
    J Clin Lab Anal; 2015 Sep; 29(5):347-52. PubMed ID: 25043869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High C-reactive protein levels are associated with depressive symptoms in schizophrenia.
    Faugere M; Micoulaud-Franchi JA; Faget-Agius C; Lançon C; Cermolacce M; Richieri R
    J Affect Disord; 2018 Jan; 225():671-675. PubMed ID: 28917193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease.
    Wang H; Yang T; Li D; Wu Y; Zhang X; Pang C; Zhang J; Ying B; Wang T; Wen F
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2369-2376. PubMed ID: 27713627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of plasma soluble urokinase plasminogen activator receptor (SuPAR) levels in ulcerative colitis.
    Erbak Yılmaz H; Aksun S; Günay S; Elmalı F; Çekiç C
    Arab J Gastroenterol; 2023 Aug; 24(3):175-179. PubMed ID: 37045728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine.
    Scharrenberg JS; Yagdiran A; Brinkmann J; Brune M; Siewe J; Jung N; Mahabir E
    J Orthop Surg Res; 2019 Nov; 14(1):367. PubMed ID: 31727136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.